DIAGNÓSTICO MOLECULAR POR REAÇÃO EM CADEIA DA POLIMERASE PARA O GENE DO CÂNCER DE MAMA TRIPLO-NEGATIVO. UMA REVISÃO DE ESCOPO.
DOI:
https://doi.org/10.61164/rmnm.v9i1.2886Palabras clave:
Reação em Cadeia da Polimerase, Neoplasias de Mama Triplo Negativas, DiagnósticoResumen
O câncer de mama é uma das apresentações neoplásicas mais comuns entre as mulheres, atingindo principalmente as de classe social mais elevada, porém tendo maior mortalidade nas pacientes de estratos socioeconômicos mais baixos. Dentre as formas de apresentação dessa neoplasia, o triplo-negativo é uma das variações com pior prognóstico e maior recidiva. A atual revisão de escopo buscou evidenciar os fatores que contribuem para o diagnóstico diferencial do câncer de mama triplo-negativo por meio da técnica molecular de reação em cadeia da polimerase (PCR). Para isso, uma busca nas bases de dados Pubmed, Embase, Scopus, Web of Science e Cochrane Library foi realizada com base na questão norteadora “Qual o papel da Reação em Cadeia da Polimerase para o diagnóstico molecular precoce do câncer de mama triplo-negativo?”. Oito artigos foram incluídos em nossa pesquisa o qual destacava a presença de VEGFA, SRC, PARP1, PTK2, RAF1, FGR3, KRAS, AZGP1, KRT19 e PIGR como principais genes envolvidos no diagnóstico diferencial desse subtipo cancerígeno. A PCR é uma técnica rápida e pouco invasiva que contribui para o acompanhamento e diagnóstico do câncer de mama triplo-negativo. Novas pesquisas devem estabelecer níveis específicos para padronização do exame com foco principalmente nos genes VEGFA, KRAS, AZGP1, KRT19 e PIGR.
Citas
Abdel-Sater F, Najar M, Fayyad-Kazan H. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status. J Cell Physiol. 2020 Jun;235(6):5204-5212. doi: 10.1002/jcp.29398. Epub 2019 Nov 17. PMID: 31736084. DOI: https://doi.org/10.1002/jcp.29398
Afghahi A, Telli ML, Kurian AW. Genetics of triple-negative breast cancer: Implications for patient care. Curr Probl Cancer. 2016 Mar-Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23. PMID: 28340968. DOI: https://doi.org/10.1016/j.currproblcancer.2016.09.007
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017 Oct 2;50(1):33. doi: 10.1186/s40659-017-0140-9. PMID: 28969709; PMCID: PMC5625777. DOI: https://doi.org/10.1186/s40659-017-0140-9
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389. PMID: 21067385. DOI: https://doi.org/10.1056/NEJMra1001389
Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer. 2012 Jan;3(1):63-70. doi: 10.1177/1947601912449832. PMID: 22893791; PMCID: PMC3415670. DOI: https://doi.org/10.1177/1947601912449832
Gomes AL de FM, Whyte MP de M, Paz WA, Rangel KK, Salles PG de O. CLINICAL-EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER AT INSTITUTO MÁRIO PENNA, BELO HORIZONTE, MINAS GERAIS. MAST [Internet]. 2020 Apr. 4 [cited 2024 Sep. 20];30:54. Available from: https://revistamastology.emnuvens.com.br/revista/article/view/416 DOI: https://doi.org/10.29289/259453942020V30S1054
Klassen AC, Smith KC. The enduring and evolving relationship between social class and breast cancer burden: a review of the literature. Cancer Epidemiol. 2011 Jun;35(3):217-34. doi: 10.1016/j.canep.2011.02.009. Epub 2011 Apr 5. PMID: 21470929. DOI: https://doi.org/10.1016/j.canep.2011.02.009
Li M, Guo Y, Feng YM, Zhang N. Identification of Triple-Negative Breast Cancer Genes and a Novel High-Risk Breast Cancer Prediction Model Development Based on PPI Data and Support Vector Machines. Front Genet. 2019 Mar 15;10:180. doi: 10.3389/fgene.2019.00180. PMID: 30930932; PMCID: PMC6428707. DOI: https://doi.org/10.3389/fgene.2019.00180
Pariyar M, Thorne RF, Scott RJ, Avery-Kiejda KA. Verification and Validation of a Four-Gene Panel as a Prognostic Indicator in Triple Negative Breast Cancer. Front Oncol. 2022 Mar 21;12:821334. doi: 10.3389/fonc.2022.821334. PMID: 35387118; PMCID: PMC8977600. DOI: https://doi.org/10.3389/fonc.2022.821334
Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 2012;7(10):e47993. doi: 10.1371/journal.pone.0047993. Epub 2012 Oct 24. PMID: 23110154; PMCID: PMC3480465. DOI: https://doi.org/10.1371/journal.pone.0047993
Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, Godwin AK, Konstantopoulou I, Nevanlinna H, Sharma P, Yannoukakos D, Yao S, Feng BJ, Tippin Davis B, Lilyquist J, Pesaran T, Goldgar DE, Polley EC, Dolinsky JS, Couch FJ. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst. 2018 Aug 1;110(8):855-862. doi: 10.1093/jnci/djy106. PMID: 30099541; PMCID: PMC6093350. DOI: https://doi.org/10.1093/jnci/djy106
Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley AM, Wheatley D, Waters S, Winter MC, Hubank M, Allen SD, Bliss JM; c-TRAK TN investigators. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22. PMID: 36423745. DOI: https://doi.org/10.1016/j.annonc.2022.11.005
Vodithala, Sahitya; Bhake, Arvind. Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction. Journal of Datta Meghe Institute of Medical Sciences University 19(1):p 71-76, Jan–Mar 2024. | DOI: 10.4103/jdmimsu.jdmimsu_703_23 DOI: https://doi.org/10.4103/jdmimsu.jdmimsu_703_23
Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, Chen Y, Cao L, Xu Q, Du X, Yang W. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. 2019 May 7;9:354. doi: 10.3389/fonc.2019.00354. PMID: 31134153; PMCID: PMC6513966. DOI: https://doi.org/10.3389/fonc.2019.00354
Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID: 34905391; PMCID: PMC8822551.
Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID: 34905391; PMCID: PMC8822551. DOI: https://doi.org/10.1259/bjr.20211033
Zaharia M, Gómez H. Triple negative breast cancer: a dificult disease to diagnose and treat. Rev Peru Med Exp Salud Publica [Internet]. 2014 Mar. 11 [cited 2024 Sep. 19];30(4). Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/247 DOI: https://doi.org/10.17843/rpmesp.2013.304.247
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Revista Multidisciplinar do Nordeste Mineiro
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
